Home - Products - Others - Other Targets - Methyl 3-hydroxy-4,5-dimethoxybenzoate

Methyl 3-hydroxy-4,5-dimethoxybenzoate

CAS No. 83011-43-2

Methyl 3-hydroxy-4,5-dimethoxybenzoate( —— )

Catalog No. M31073 CAS No. 83011-43-2

Methyl 3-hydroxy-4,5-dimethoxybenzoate shows fairly active for oxidation resistance in the presence of H2O2.

Methyl 3-hydroxy-4,5-dimethoxybenzoate shows fairly active for oxidation resistance in the presence of H2O2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 82 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Methyl 3-hydroxy-4,5-dimethoxybenzoate
  • Note
    Research use only, not for human use.
  • Brief Description
    Methyl 3-hydroxy-4,5-dimethoxybenzoate shows fairly active for oxidation resistance in the presence of H2O2.
  • Description
    Methyl 3-hydroxy-4,5-dimethoxybenzoate shows fairly active for oxidation resistance in the presence of H2O2. It shows obvious antimicrobial activities, the minimum inhibitory concentration of it is 5 mg/ml against Staphylococcus aureus and Rhizopus, and 10 mg/ml against E. coli.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    83011-43-2
  • Formula Weight
    212.2
  • Molecular Formula
    C10H12O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Cyclo(Phe-Leu)

    Cyclo(Phe-Leu) is a new cell cycle inhibitor.

  • Inaxaplin

    Inaxaplin is an apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.

  • DSG Crosslinker

    DSG Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).